Payment overview · 2025
General Payments
$54,277.45
229 reported records · 21 companies
Healthcare provider profile · identity verified
Steven E Katz, MD
Allopathic & Osteopathic Physicians|Ophthalmology · COLUMBUS, OH · NPI 1518906866
Verified facts
What the public records show
CMS Open Payments records show Steven E Katz, MD received $54,277.45 in general payments during 2025 across 229 reported records.
Amgen Inc. accounted for 72.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Cequa, Nurtec Odt, Qulipta, Rocklatan, Tepezza, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Ubrelvy by this doctor in 2024.
ARGENX US, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VYVGART as an associated drug or biological on 6851 records involving 2825 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vyvgart by this doctor in 2024.
Alcon Vision LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rocklatan as an associated drug or biological on 12237 records involving 5351 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Rocklatan by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEPEZZA as an associated drug or biological on 32661 records involving 9684 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Tepezza by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MIEBO as an associated drug or biological on 34133 records involving 12967 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Miebo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Nurtec Odt by this doctor in 2024.
SUN PHARMACEUTICAL INDUSTRIES INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Cequa as an associated drug or biological on 25765 records involving 9461 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Cequa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $39,104.11 | 72.0% | 56 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $8,807.82 | 16.2% | 62 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $4,408.07 | 8.1% | 11 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $343.05 | 0.6% | 13 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $339.82 | 0.6% | 21 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $278.99 | 0.5% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $272.69 | 0.5% | 17 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $137.62 | 0.2% | 8 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $133.10 | 0.2% | 6 | 2025 |
| Alcon Vision LLC | Unresolved — no canonical attribution shown | $86.39 | 0.2% | 3 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $65.77 | 0.1% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $57.33 | 0.1% | 3 | 2025 |
| Harrow Eye, LLC | Unresolved — no canonical attribution shown | $50.23 | 0.1% | 2 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $42.31 | 0.1% | 2 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $35.26 | 0.1% | 2 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $33.49 | 0.1% | 2 | 2025 |
| Oyster Point Pharma, Inc. | Unresolved — no canonical attribution shown | $19.59 | 0.0% | 1 | 2025 |
| Bausch & Lomb Americas Inc. | Unresolved — no canonical attribution shown | $17.00 | 0.0% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $16.09 | 0.0% | 1 | 2025 |
| DePuy Synthes Sales Inc. | Unresolved — no canonical attribution shown | $14.42 | 0.0% | 1 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $14.30 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $43,587.50 | 18 |
| Consulting Fee | $4,200.00 | 1 |
| Food and Beverage | $4,178.52 | 204 |
| Travel and Lodging | $2,136.24 | 4 |
| Education | $175.19 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $39,104.11 | 56 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $5,302.66 | 50 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $4,408.07 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $3,870.01 | 51 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $343.05 | 13 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $278.99 | 12 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $272.69 | 17 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $252.19 | 16 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $225.11 | 18 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $137.62 | 8 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $133.10 | 6 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $57.33 | 3 | 2025 |
Source payment records
|
|||||
| Enspryng Normalized: enspryng |
Biological | Genentech USA, Inc. | $52.01 | 3 | 2025 |
Source payment records
|
|||||
| VEVYE Normalized: vevye |
Drug | Harrow Eye, LLC | $50.23 | 2 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $42.31 | 2 | 2025 |
Source payment records
|
|||||
| Rocklatan Normalized: rocklatan |
Drug | Alcon Vision LLC | $34.28 | 1 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $33.49 | 2 | 2025 |
Source payment records
|
|||||
| TRYPTYR Normalized: tryptyr |
Drug | Alcon Vision LLC | $30.42 | 1 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $27.22 | 2 | 2025 |
Source payment records
|
|||||
| EYSUVIS Normalized: eysuvis |
Drug | Alcon Vision LLC | $21.69 | 1 | 2025 |
Source payment records
|
|||||
| GOMEKLI Normalized: gomekli |
Drug | SpringWorks Therapeutics, Inc. | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| RYZUMVI Normalized: ryzumvi |
Drug | Oyster Point Pharma, Inc. | $19.59 | 1 | 2025 |
Source payment records
|
|||||
| TYRVAYA Normalized: tyrvaya |
Drug | Oyster Point Pharma, Inc. | $19.59 | 1 | 2025 |
Source payment records
|
|||||
| XIIDRA Normalized: xiidra |
Drug | Bausch & Lomb Americas Inc. | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| ENTYVIO Normalized: entyvio |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| TRUMATCH Normalized: trumatch |
Device | DePuy Synthes Sales Inc. | $14.42 | 1 | 2025 |
Source payment records
|
|||||
| Cequa Normalized: cequa |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $14.30 | 1 | 2025 |
Source payment records
|
|||||
| Actemra Normalized: actemra |
Biological | Genentech USA, Inc. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
| LUMIGAN Normalized: lumigan |
Drug | ABBVIE INC. | $11.02 | 2 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $11.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Cequa cequa |
2025 | Cequa | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 39 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 99 | exact normalized | Medicare Part D |
| Rocklatan rocklatan |
2025 | Rocklatan | 2024 | 73 | exact normalized | Medicare Part D |
| TEPEZZA tepezza |
2025 | Tepezza | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 63 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
99 | 24 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
63 | 23 |
| ARGENX US, INC. Exact reporting entity; no affiliate inference |
2025 | VYVGART open payments reported associated product |
CMS Open Payments — General Payments 6851 supporting records · 2825 recipient NPIs · example record 1240416066 |
Vyvgart · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Alcon Vision LLC Exact reporting entity; no affiliate inference |
2025 | Rocklatan open payments reported associated product |
CMS Open Payments — General Payments 12237 supporting records · 5351 recipient NPIs · example record 1207357016 |
Rocklatan · 2024 Exact normalized brand match · 1 Part D row |
73 | 16 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | TEPEZZA open payments reported associated product |
CMS Open Payments — General Payments 32661 supporting records · 9684 recipient NPIs · example record 1226871638 |
Tepezza · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | MIEBO open payments reported associated product |
CMS Open Payments — General Payments 34133 supporting records · 12967 recipient NPIs · example record 1254730224 |
Miebo · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
39 | 14 |
| SUN PHARMACEUTICAL INDUSTRIES INC. Exact reporting entity; no affiliate inference |
2025 | Cequa open payments reported associated product |
CMS Open Payments — General Payments 25765 supporting records · 9461 recipient NPIs · example record 1250962431 |
Cequa · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 144 | 70 |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 141 | 86 |
| Latanoprost | Latanoprost | 100 | 24 |
| Qulipta | Atogepant | 99 | 24 |
| Timolol Maleate | Timolol Maleate | 87 | 14 |
| Topiramate | Topiramate | 77 | 31 |
| Rocklatan | Netarsudil Mesylat/Latanoprost | 73 | 16 |
| Brimonidine Tartrate | Brimonidine Tartrate | 72 | 21 |
| Restasis | Cyclosporine | 72 | 25 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 67 | 28 |
| Ubrelvy | Ubrogepant | 63 | 23 |
| Erythromycin | Erythromycin Base | 47 | 36 |
| Nurtec Odt | Rimegepant Sulfate | 39 | 14 |
| Propranolol Hcl Er | Propranolol Hcl | 29 | suppressed |
| Acetazolamide Er | Acetazolamide | 28 | 12 |
| Furosemide | Furosemide | 27 | 11 |
| Cyclosporine | Cyclosporine | 22 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 21 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 21 | suppressed |
| Cequa | Cyclosporine | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Miebo | Perfluorohexyloctane/Pf | 17 | suppressed |
| Gabapentin | Gabapentin | 16 | suppressed |
| Restasis Multidose | Cyclosporine | 15 | suppressed |
| Vyvgart | Efgartigimod Alfa-Fcab | 14 | suppressed |
| Potassium Chloride | Potassium Chloride | 12 | suppressed |
| Acetazolamide | Acetazolamide | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Pyridostigmine Bromide Er | Pyridostigmine Bromide | 11 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 11 | suppressed |
| Tepezza | Teprotumumab-Trbw | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $54,277.45 · 229 records | Amgen Inc. | ACTHAR, AJOVY, AUSTEDO XR, Actemra, BOTOX, Cequa, ENTYVIO, EYSUVIS, Enspryng, GOMEKLI, LUMIGAN, NURTEC ODT, PURIFIED CORTROPHIN GEL, QULIPTA, RYZUMVI, Rocklatan, Symbravo, TEPEZZA, TRUDHESA, TRUMATCH, TRYPTYR, TYRVAYA, UBRELVY, ULTOMIRIS, VEVYE, VYEPTI, VYVGART HYTRULO, XIIDRA, Xeomin, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Cequa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error